Teva: fine of 462 million euros from Brussels for anti-competitive activities

The European Commission has just imposed a fine of 462.6 million euros on the Israeli pharmaceutical group Teva for having abused its dominant position in order to delay competition to its flagship drug for the treatment of multiple sclerosis, Copaxone.



Brussels accuses the Israeli laboratory of having artificially extended patent protection for Copaxone and systematically disseminating misleading information on a competing product in order to hinder its entry into the market and its adoption.

  Pascal Lemontel

 WE RECOMMEND YOU

  > National Eczema Day: Therapeutic progress!

The first case of the West Nile virus this year has been recorded in the Pyrénées-Orientales.

Public Health France confirmed this week the first locally acquired case of West Nile virus in mainland France in 2026. The patient was infected in the Pyrénées-Orientales department. The virus, transmitted ...

The sunscreens sold by Temu, Shein and AliExpress are very dangerous for your health.

The consumer advocacy group Que Choisir Ensemble tested ten sunscreens recently sold on Temu, AliExpress, and Shein. According to the group, none of the products offer satisfactory protection. Nine sunscreens ...

Ebola: The first case in France is "cured"

The first case of Ebola detected in France, a humanitarian doctor who returned from the Democratic Republic of Congo on June 23, has now recovered after two negative PCR tests and has been discharged from ...

Migraine: what are the triggering factors?

You know that throbbing headache all too well, that excruciating pain that can last for hours: a migraine. Each migraine attack involves one or more diff